Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 2
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 (anti-Nogo-A monoclonal antibody) Administered by IV Infusion to Subjects With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Enrolment: 3 · Results not recorded
Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 (anti-Nogo-A monoclonal antibody) in Patients With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Enrolment: 3 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionOther / unspecifiedC57BL/6Acute inhibition after oxygen-induced retinopathy; exact timing not stated in t…
Model: Oxygen-induced retinopathy, producing defined zones of retinal ischaemia
Acute inhibition of Nogo-A with the function-blocking antibody 11C7 significantly improved vascular regeneration, prevented pathological pre-retinal angiogenesis and restored retinal function measured electrophysiologically.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
